Rcadia Medical Imaging, Ltd. Announces Initial U.S. COR Analyzer Beta Site
Posted on: Thursday, 1 November 2007, 09:01 CDT
BOSTON, Nov. 1 /PRNewswire/ -- Rcadia Medical Imaging, Ltd., developer and marketer of innovative, patented computer-aided diagnostic software, announces the first installation of its COR Analyzer at St. James Healthcare in Butte, Montana.
Rcadia's COR Analyzer performs automatic segmentation and tracking of the coronary artery tree for Coronary CT angiogram (CTA) procedures without human intervention. The COR Analyzer system detects stenotic lesions in the major coronary arteries and automatically identifies patients without coronary artery disease with a very high negative predictive value. It uses proprietary image processing algorithms to produce a report that assists physicians accurately and quickly in evaluating patients with suspected coronary artery disease.
"The recent interest in using Coronary CTA in patients with acute chest pain has created a major need for interpreting these studies in a timely manner. Initial results with the Rcadia system at our center have been extremely positive. We are optimistic that the COR Analyzer will address many of the workflow issues in our practice," commented Anna Chacko, MD, Chief of Radiology at St. James Healthcare.
Rcadia's COR Analyzer is installed as a beta site at MNAP Diagnostics in Pennsylvania, with additional beta installations planned for November. "Beta sites will provide us with information to optimize and fine-tune the system to support physician workflow," noted Rcadia CEO, Shai Levanon. Levanon added, "We are currently setting up our distribution and technical support team in the U.S. and expect to initiate sales of the COR Analyzer system in the very near future."
Rcadia Medical Imaging, Ltd.
CONTACT: Jeanne-Marie Phillips of HealthFlash Marketing for RcadiaMedical Imaging, Ltd., +1-888-655-3434, jphillips@healthflashmarketing.com
Source: PRNewswire
Related Articles
- CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System
- Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
- Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients With Type 1 and Type 2 Diabetes
- TAXUS(R) Liberte(TM) Drug-Eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
- Dextroscope(R) Changes the Neurosurgical Planning Paradigm; 3D Virtual Reality System Puts Patients Images in the Surgeon's Hands
- TAXUS(R) Coronary Stent System Cited By EuroIntervention for Superiority in Diabetic Patients
- VeriChip Corporation's VeriMed System for Patient Identification Selected By 13 New Hospitals; 97 Healthcare Facilities Have Now Agreed to Implement the VeriMed Patient Identification System
- FlowMedica Announces New Physician-Sponsored Study of Its Benephit Infusion System in Patients With Renal Insufficiency
- Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
- Naval Research Laboratory First to Install 128-Processor Single System Image Altix 3000 Supercomputer
 |
 |
User Comments (0)
RSS Feeds